The Oncology Department provides treatment for various cancers: gynecologic, urologic, gastrointestinal, brain tumors, and lymphomas.
Since 2023, within the new UPPO structure (Early Phase Oncology Unit), authorization has been granted to conduct early therapeutic studies, including first-in-human clinical trials. In 2024, under the auspices of FOCH, trials began for metastatic pancreatic cancer, testing a new immunotherapy combined with chemotherapy.
Head of Department: Professor Jaafar BENNOUNA.
Main areas:
- Surgical oncology
- Da Vinci Xi robot – for prostate, bladder, and gynecologic cancer surgeries
- Laparoscopic and thoracic procedures – for lung, stomach, and intestinal cancers
- Drug therapy
- Chemotherapy, targeted therapy, immunotherapy (e.g., PD-1/PD-L1 inhibitors)
- Radiotherapy
- TrueBeam – high-precision radiotherapy system (accuracy 0.5 mm)
- Proton therapy – for pediatric tumors and complex locations
- Transplant oncology
- Organ transplantation in cases with concomitant oncology (e.g., after liver cancer treatment)